Five GLP‐1 mimetic agents are approved for the treatment of type 2 diabetes, including exenatide, lixisenatide, liraglutide, dulaglutide and semaglutide (Boer & Holst, 2020). Here, GLP1R is linked to type 2 diabetes mellitus.